Dosage and Administration
Dosage for Patients with Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia (HABP/VABP)
The recommended dose of ZERBAXA in adult patients with HABP/VABP and creatinine clearance (CrCl) greater than 50 mL/min is 3 grams (two 1.5 g vials) over 1-hour period every 8 hours for 8 to 14 days.


Renal Dosing Adjustments for Patients with HABP/VABP per Estimated CrCl (mL/min)a,b
- 30 to 50 1.5 g (1 g and 0.5 g) intravenously every 8 hours
- 15 to 29 750 mg (500 mg and 250 mg) intravenously every 8 hours
- For patients with end-stage renal disease on hemodialysis: a single loading dose of 2.25 g (1.5 g and 0.75 g) followed by a 450-mg (300 mg and 150 mg) maintenance dose administered every 8 hours for the remainder of the treatment period (on hemodialysis days, administer the dose at the earliest possible time following completion of dialysis).
aCreatinine clearance (CrCl) estimated using Cockcroft-Gault formula.
bAll doses of ZERBAXA are administered over 1 hour.
3-g Dose Selected Based on Phase 1 PK/PD Study

- ZERBAXA at 3-g IV dose acheived target concentration above ceftolozane minimum inhibitory concentration (MIC) in the epithelial lining fluid (ELF) over 100% of the dosing interval.
PK/PD Study Design
- Following 1-hour intravenous infusions of ZERBAXA 3 g (ceftolozane 2 g and tazobactam 1 g) or adjusted based on renal function every 8 hours in ventilated patients with confirmed or suspected pneumonia (N=22), mean pulmonary epithelial lining fluid-to-free plasma AUC ratios of ceftolozane and tazobactam were approximately 50% and 62%, respectively, and are similar to those in healthy subjects (approximately 61% and 63%, respectively) receiving ZERBAXA 1.5 g (ceftolozane 1 g and tazobactam 0.5 g)
- Minimum ceftolozane and tazobactam epithelial lung lining fluid concentrations in ventilated subjects at the end of the dosing interval were 8.2 mcg/mL and 1.0 mcg/mL, respectively